DK3139963T3 - Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme - Google Patents
Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme Download PDFInfo
- Publication number
- DK3139963T3 DK3139963T3 DK15709742.9T DK15709742T DK3139963T3 DK 3139963 T3 DK3139963 T3 DK 3139963T3 DK 15709742 T DK15709742 T DK 15709742T DK 3139963 T3 DK3139963 T3 DK 3139963T3
- Authority
- DK
- Denmark
- Prior art keywords
- prodrugs
- conjugates
- cancer
- treatment
- inflammatory diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1450956A FR3017298B1 (fr) | 2014-02-07 | 2014-02-07 | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
| PCT/IB2015/050914 WO2015118497A1 (fr) | 2014-02-07 | 2015-02-06 | Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3139963T3 true DK3139963T3 (da) | 2020-10-26 |
Family
ID=50829100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15709742.9T DK3139963T3 (da) | 2014-02-07 | 2015-02-06 | Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme |
| DK20192895.9T DK3766510T3 (da) | 2014-02-07 | 2015-02-06 | Konjugater og prodrugs til anvendelse ved behandling af cancer og inflammatoriske sygdomme |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20192895.9T DK3766510T3 (da) | 2014-02-07 | 2015-02-06 | Konjugater og prodrugs til anvendelse ved behandling af cancer og inflammatoriske sygdomme |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10293021B2 (enExample) |
| EP (2) | EP3766510B1 (enExample) |
| JP (1) | JP6721512B2 (enExample) |
| CN (2) | CN106573071A (enExample) |
| CA (1) | CA2938501C (enExample) |
| DK (2) | DK3139963T3 (enExample) |
| ES (2) | ES2843798T3 (enExample) |
| FI (1) | FI3766510T3 (enExample) |
| FR (1) | FR3017298B1 (enExample) |
| LT (1) | LT3766510T (enExample) |
| PT (1) | PT3766510T (enExample) |
| WO (1) | WO2015118497A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11384104B2 (en) | 2015-06-19 | 2022-07-12 | Centurion Biopharma Corporation | Delivery systems for controlled drug release |
| WO2017058808A1 (en) * | 2015-10-02 | 2017-04-06 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
| ES2948846T3 (es) | 2016-03-29 | 2023-09-20 | Toray Industries | Derivado peptídico y uso del mismo |
| US11666657B2 (en) | 2017-05-16 | 2023-06-06 | Universite De Strasbourg | Protein-drug conjugates and their use in the treatment of cancers |
| BR112020009836A2 (pt) * | 2017-11-30 | 2020-10-13 | Centurion Biopharma Corporation | pró-drogas de ligação a albumina de derivados de auristatina e |
| HRP20241363T1 (hr) * | 2018-04-03 | 2024-12-20 | Syndivia | Konjugat citotoksičnog lijeka i oblik predlijeka navedenog konjugata |
| CA3139378A1 (en) | 2019-05-06 | 2020-11-12 | Seekyo | New therapeutic vectors and prodrugs for treating cancers |
| FR3126982B1 (fr) * | 2021-09-14 | 2023-09-15 | Centre Nat Rech Scient | Vecteurs ciblant la beta-d-n-acetylglucosaminidase |
| CN116077674B (zh) * | 2022-12-26 | 2025-03-25 | 北京大学 | 生物分子-聚氮氧化物偶联物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| HUE035853T2 (en) * | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| FR2960153B1 (fr) * | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
-
2014
- 2014-02-07 FR FR1450956A patent/FR3017298B1/fr not_active Expired - Fee Related
-
2015
- 2015-02-06 EP EP20192895.9A patent/EP3766510B1/fr active Active
- 2015-02-06 JP JP2016550736A patent/JP6721512B2/ja active Active
- 2015-02-06 CN CN201580018638.0A patent/CN106573071A/zh active Pending
- 2015-02-06 PT PT201928959T patent/PT3766510T/pt unknown
- 2015-02-06 CA CA2938501A patent/CA2938501C/fr active Active
- 2015-02-06 WO PCT/IB2015/050914 patent/WO2015118497A1/fr not_active Ceased
- 2015-02-06 DK DK15709742.9T patent/DK3139963T3/da active
- 2015-02-06 ES ES15709742T patent/ES2843798T3/es active Active
- 2015-02-06 FI FIEP20192895.9T patent/FI3766510T3/fi active
- 2015-02-06 EP EP15709742.9A patent/EP3139963B1/fr active Active
- 2015-02-06 US US15/117,069 patent/US10293021B2/en active Active
- 2015-02-06 ES ES20192895T patent/ES3074632T3/es active Active
- 2015-02-06 LT LTEP20192895.9T patent/LT3766510T/lt unknown
- 2015-02-06 CN CN202210334259.4A patent/CN114917358A/zh active Pending
- 2015-02-06 DK DK20192895.9T patent/DK3766510T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3766510T (pt) | 2026-07-17 |
| EP3139963A1 (fr) | 2017-03-15 |
| EP3139963B1 (fr) | 2020-10-07 |
| FR3017298B1 (fr) | 2016-03-04 |
| FI3766510T3 (fi) | 2026-07-08 |
| LT3766510T (lt) | 2026-07-27 |
| EP3766510A1 (fr) | 2021-01-20 |
| ES2843798T3 (es) | 2021-07-20 |
| US10293021B2 (en) | 2019-05-21 |
| JP2017506628A (ja) | 2017-03-09 |
| CN114917358A (zh) | 2022-08-19 |
| CA2938501C (fr) | 2022-04-05 |
| CN106573071A (zh) | 2017-04-19 |
| US20170095525A1 (en) | 2017-04-06 |
| DK3766510T3 (da) | 2026-06-29 |
| JP6721512B2 (ja) | 2020-07-15 |
| CA2938501A1 (fr) | 2015-08-13 |
| FR3017298A1 (fr) | 2015-08-14 |
| EP3766510B1 (fr) | 2026-05-13 |
| ES3074632T3 (es) | 2026-07-22 |
| WO2015118497A1 (fr) | 2015-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296080B1 (en) | Method for treating cancer | |
| IL255261A0 (en) | Methods for treating cancer | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| HUE049072T2 (hu) | AXL-specifikus ellenanyag-drog konjugátumok rák kezelésére | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| HUE059694T2 (hu) | Készítmény rák kezelésére | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| PL3197456T3 (pl) | Leczenie nowotworów | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| HRP20181525T1 (hr) | Postupak pročišćavanja konjugata cys-vezanih konjugata protutijelo-lijek | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK3622953T3 (da) | Kombinationsbehandling af cancer | |
| EP3546020C0 (en) | CANCER TREATMENT DEVICE | |
| EP3413927A4 (en) | CANCER THERAPY | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| DK3400072T3 (da) | Formuleringer til behandling af blærecancer | |
| DK3576740T3 (da) | Cancerbehandling | |
| HUE040167T2 (hu) | Rákkezelés | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT |